BioXcel Therapeutics CFO Richard Steinhart Granted 9,000 RSUs

On August 1, 2025, BioXcel Therapeutics, Inc. (BTAI) granted 9,000 Restricted Stock Units (RSUs) to Richard I. Steinhart, the company's Chief Financial Officer. Each RSU represents a contingent right to receive one share of the company's Common Stock. The RSUs are set to vest 100% on or within thirty days of May 1, 2026, which is nine months from the grant date, provided that Steinhart remains employed by the company or its subsidiary on that date. This transaction was reported in a Form 4 filing with the SEC on August 5, 2025.